Triple
T18213151
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | vincristine |
E436082
|
entity |
| Predicate | usedInRegimen |
P25490
|
FINISHED |
| Object | MOPP chemotherapy regimen |
—
|
NE NERFINISHED |
How this triple was built (3 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: MOPP chemotherapy regimen | Statement: [vincristine, usedInRegimen, MOPP chemotherapy regimen]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: MOPP chemotherapy regimen Context triple: [vincristine, usedInRegimen, MOPP chemotherapy regimen]
-
A.
VAC chemotherapy regimen
The VAC chemotherapy regimen is a combination cancer treatment protocol that typically includes vincristine, actinomycin D (dactinomycin), and cyclophosphamide, commonly used for pediatric solid tumors such as rhabdomyosarcoma.
-
B.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
C.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
D.
ABVD regimen
The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
-
E.
FOLFIRI regimen
The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: MOPP chemotherapy regimen Target entity description: The MOPP chemotherapy regimen is an early combination cancer treatment protocol, historically used for Hodgkin lymphoma, that includes multiple cytotoxic drugs administered in cycles.
-
A.
VAC chemotherapy regimen
The VAC chemotherapy regimen is a combination cancer treatment protocol that typically includes vincristine, actinomycin D (dactinomycin), and cyclophosphamide, commonly used for pediatric solid tumors such as rhabdomyosarcoma.
-
B.
BEACOPP regimen
The BEACOPP regimen is an intensive multi-drug chemotherapy protocol used primarily for advanced-stage Hodgkin lymphoma.
-
C.
R-CHOP
R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.
-
D.
ABVD regimen
The ABVD regimen is a standard chemotherapy combination used as first-line treatment for classical Hodgkin lymphoma.
-
E.
FOLFIRI regimen
The FOLFIRI regimen is a combination chemotherapy protocol, typically including folinic acid, fluorouracil, and irinotecan, commonly used to treat advanced colorectal cancer.
- F. None of above. chosen
Provenance (2 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69d8b90dba6481908e119eb9aa4ca0cb |
completed | April 10, 2026, 8:47 a.m. |
| NER | Named-entity recognition | batch_69e4e22a26308190a6720b41a9bbfc2d |
completed | April 19, 2026, 2:09 p.m. |
Created at: April 10, 2026, 10:32 a.m.